Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. - Wikidata - awgldk - TriplyDB

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.

http://www.wikidata.org/entity/Q34392488

about

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.Mitochondrial apoptosis and BH3 mimetics The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia Acid ceramidase is upregulated in AML and represents a novel therapeutic target.Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia.MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.Emerging therapies for acute myeloid leukemia.Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199.Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199 A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.Rational Combinations of Targeted Agents in AML Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition Bcl-xL controls a switch between cell death modes during mitotic arrest Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells.BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis.Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics.Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors.Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines.Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models A Standardized Chemically Modified Curcuma longa Extract Modulates IRAK-MAPK Signaling in Inflammation and Potentiates Cytotoxicity.Acute myeloid leukemia: advancing clinical trials and promising therapeutics.The La protein counteracts cisplatin-induced cell death by stimulating protein synthesis of anti-apoptotic factor Bcl2.

P2860

Q27010154-77277BA6-4FCA-4588-B47D-D549E69E2413 Q27853319-74A6B441-D1EE-45F8-8362-785383E93424 Q28069552-BC85DE8D-9A53-4352-A7B1-E88968F8A0BD Q28075504-EDA234EA-0643-413C-B442-15705404F196 Q28548058-90DF92E3-1889-45C1-9115-761AE5FF5F67 Q28554677-F361C7CC-5563-4982-ADAD-E5BB48A01F5D Q30275460-89FBC589-2704-40E7-94B5-59512FBA6989 Q30361951-0DE5655B-7B1F-4F80-955A-6D84D826F650 Q30827619-44B8EDFC-3BC6-4956-A961-B1AA5D63F68A Q33419789-F7FC4631-5E43-44BB-BB50-3A7DCCF91604 Q33576363-D1AB4C7C-398C-455A-BDF1-8CB8149240ED Q33702409-55D52B39-AE04-46F3-AE33-E831782C163A Q33840360-89E2F9A6-5E2A-4354-95E2-9CBEF028CDAE Q33875554-9813B0F8-2A60-42D5-BBF8-1642B4CB4C87 Q33983255-4955B44D-EC28-4C46-88F0-45D8E8497E39 Q34135298-FF2F83B1-D1B7-4C4A-9932-A21ADAB28C02 Q34398390-F3B5DAD2-BEEF-42B1-AA8A-90983E67D8F3 Q34543038-8FD77E9A-F205-4A2A-A49B-16BDB064436F Q35159034-B0329CA2-8770-420D-A8CC-7577D1CF6C4D Q35524250-CC69F241-6896-4A3A-97BE-1FD8A267E169 Q35750491-CCF9B1AE-8645-4274-AF79-5EA3FF052168 Q35859229-07C75754-3A94-4DEC-8774-5013F778E24C Q35861111-1E5DD645-2800-4E83-8E1A-3937620FD14E Q36169778-ADC2A133-C340-47C1-A336-2B99DD6FF5B9 Q36179601-17032BB6-43A2-40B6-996F-BF0D3CFC6563 Q36199633-00F27823-946F-4DD2-A1F7-E81B3BD90701 Q36284637-1D9C1D54-BFF5-4A67-A64A-5620D92B3CD7 Q36337587-0AF6646C-1EED-4F11-9AA0-6D20E0E88C19 Q36426910-EF366DCA-05F5-4B63-ABEA-0F6B67E35F43 Q36468244-74554C1A-AC25-4156-AE74-EA13DD727423 Q36601134-EB53F799-4E5F-439D-B39F-C17788D73B70 Q36642752-CAA2FCFC-172F-4E81-BBAA-D5CE0CEEECEC Q36748678-0056E9EB-12AC-441A-96B8-CC7F84E8AF3F Q36751575-F0A19822-5852-4B40-AD6A-55D9A09E5D8B Q36990787-9C057EFD-6947-4FB6-89EF-EB93C93F40CA Q36998291-7076D686-1A93-4DA6-B51A-F7B8B5113204 Q37045295-93CF4ACB-FB7C-4873-8636-31BC05885D76 Q37122453-90AFF405-E91C-4A91-8F00-4737C48E1FE6 Q37221579-23B0AE20-480B-4CBB-AF4A-C798B10B0352 Q37301910-50824BAB-F0CD-4A08-804B-C8EBBBFB70F9

P2860

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.

http://www.wikidata.org/entity/Q34392488

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Selective BCL-2 inhibition by ...... ath in acute myeloid leukemia.

@ast

Selective BCL-2 inhibition by ...... ath in acute myeloid leukemia.

@en

Selective BCL-2 inhibition by ...... ath in acute myeloid leukemia.

@nl

type

label

Selective BCL-2 inhibition by ...... ath in acute myeloid leukemia.

@ast

Selective BCL-2 inhibition by ...... ath in acute myeloid leukemia.

@en

Selective BCL-2 inhibition by ...... ath in acute myeloid leukemia.

@nl

prefLabel

Selective BCL-2 inhibition by ...... ath in acute myeloid leukemia.

@ast

Selective BCL-2 inhibition by ...... ath in acute myeloid leukemia.

@en

Selective BCL-2 inhibition by ...... ath in acute myeloid leukemia.

@nl

P1433

Q34392488-9E083302-49AE-4ECA-B50B-509A1567F5C4

P1476

Q34392488-3404E064-8EAA-4356-B0CA-6933EB02D3F9

P2093

Q34392488-02F6B850-8293-4B60-BB00-15C737558545

Q34392488-0479662E-91B1-4806-AD00-98FA25F02267

Q34392488-1DDCC884-6766-4414-B510-51890439EFFC

Q34392488-2DE72F93-5882-4EC8-9951-27C1BF9C776F

Q34392488-389E69B8-27C5-4AC1-B9E9-AB7CC6A56F29

Q34392488-3ACC1086-66F6-48D0-B4F4-423F276A0571

Q34392488-3C1C5A9D-E17C-49AD-9BDB-45C184A7F56F

Q34392488-45F294E9-4440-454D-8CA1-C553AA2CFBEA

Q34392488-5A4540A1-CC12-4D3C-ACBF-3167DDF5DF43

Q34392488-5B1EB3BE-8E3D-4852-8E2A-9E1554792114

P2860

Q34392488-09F7AB6D-8ADC-490D-9ADC-810B186ED492

Q34392488-0ED7EDD2-BB47-4750-A74F-468C3C0DB7BD

Q34392488-1FF820C9-6BBC-4D22-ACC2-EE4067ED5662

Q34392488-215737B2-847E-4166-8FD1-347B1EE11353

Q34392488-21CEE482-AF79-436A-8571-B03546A2374D

Q34392488-34558AA1-D880-4F52-BEC5-B8D0C7DBE3F8

Q34392488-4200EC6A-E2F0-4651-A27C-F91C796A7331

Q34392488-562746A2-BFB3-414E-A0A5-8F81CA9D2A4D

Q34392488-61683799-09A4-468B-89E8-1B8BD7665C60

Q34392488-7696E6A1-6D89-41F3-B9EB-8DEE8774DF2B

P304

Q34392488-50FC093C-D1D3-4985-873D-4EF761A26F51

P31

Q34392488-AC0DCD65-6D6F-4887-B8C7-805B520106F7

P356

Q34392488-54A28605-8A29-4CB9-BFE3-4C5BA90F0431

P433

Q34392488-0AFE7104-06C8-445C-90C4-924DE1C6C43D

P478

Q34392488-CDC09C35-7AE2-4C7C-9B5A-36938640FE30

P50

Q34392488-053E5557-525A-4D5C-8FE4-D2A76AE3FBD0

Q34392488-29090FBD-25AD-418E-9E1E-70FD19361008

Q34392488-31736CD7-4C6B-4428-966D-6CCCCC07D307

Q34392488-4023DD48-4A25-4707-BC4B-734A8F05A471

Q34392488-4B822DDE-9CF9-4FD5-AB2D-C35D7DF1F122

Q34392488-5E53F8AA-930C-4A6A-B96E-62D84459D5FD

Q34392488-7C46A54C-9E0D-4C8B-9085-3DA14484E3D5

Q34392488-9E332D84-23C3-40CE-8E8F-CE0A5E4BDD80

Q34392488-A0955DB4-193E-4B50-BDC5-64D877028DB4

Q34392488-A270ECC6-4806-414A-9EAD-AB15B6800385

P577

Q34392488-FF1C3F79-DB32-4503-9E34-8C534655D2EB

P698

Q34392488-573BB944-1B17-496C-9F68-02BD2DC3D1EA

P921

Q34392488-646AD0E4-5DD9-428B-9443-B961EFA2EBE4

P932

Q34392488-734B4A04-73C6-4958-8B5D-C680A40121E9

P356

2159-8290.CD-13-0609

P1433

Cancer Discovery

P1476

Selective BCL-2 inhibition by ...... ath in acute myeloid leukemia.

@en

P2093

Anthony G Letai

http://www.w3.org/2001/XMLSchema#string

Daniel J DeAngelo

http://www.w3.org/2001/XMLSchema#string

Donna Bucci

http://www.w3.org/2001/XMLSchema#string

Eugene Park

http://www.w3.org/2001/XMLSchema#string

Hong Mu

http://www.w3.org/2001/XMLSchema#string

Ilene Galinsky

http://www.w3.org/2001/XMLSchema#string

Jeremy Ryan

http://www.w3.org/2001/XMLSchema#string

Jianhua Hu

http://www.w3.org/2001/XMLSchema#string

Joel D Leverson

http://www.w3.org/2001/XMLSchema#string

Juliana M Benito

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics

P304

362-375

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-13-0609

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Patrick A Zweidler-McKay

Markus Müschen

Jorge Eduardo Cortes

Hagop Kantarjian

Gautam Borthakur

Torsten Haferlach

Marina Konopleva

Hartmut Döhner

P577

2013-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24346116

http://www.w3.org/2001/XMLSchema#string

P921

P932

3975047

http://www.w3.org/2001/XMLSchema#string